Home - Australian Pharmacist

Aged care in focus

Thea Cowie - 6 October 2019

Industry

The Royal Commission into Aged Care Quality and Safety has heard clear calls for pharmacists, as a priority, to spend more time on the...

Opinion: When a natural disaster hits

Jessica Burrey MPS - 5 February 2020

Industry

Dispensing from a house, a library and evacuation centres: that’s what happens in a flood. It’s almost 10 years since a flood put the majority...

Q&A: Shadow Federal Health Minister Catherine King

Jarryd Luke - 1 February 2018

People

As a supporter of pharmacists, Catherine King MP is a firm believer in having a ‘broader’ role for pharmacists in Australia’s health system. During her...

Resistance movement: Pharmacy’s fight against antimicrobial resistance

Joshua Hoey - 27 February 2018

Clinical

Antimicrobial resistance (AMR) has been ranked as serious a threat to society as terrorism. With millions of lives at risk, and trillions in GDP...

Taking an idea to reality

Joshua Hoey - 21 October 2018

Industry

The winner of the first PSA Shark Tank is no minnow. SetDose has a $42 billion problem in its sights: medication and dosing errors. To...

Thousands suffering from undiagnosed type 2 diabetes

Mikaela Dery - 5 August 2019

Clinical

The CEO of Diabetes Australia, Professor Greg Johnson, recently called attention to the high numbers of Australians living with undiagnosed type 2 diabetes. In a...

1...277278279...331 Page 278 of 331

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What is diphtheria?

What are the symptoms?

How dangerous is the disease?

Was it once eradicated in Australia?

Why has there been a resurgence?

Can diphtheria be treated?

Who is most at risk?

What are the risks of an outbreak here?

How often are booster doses required?

What can pharmacists do?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What is diphtheria?

What are the symptoms?

How dangerous is the disease?

Was it once eradicated in Australia?

Why has there been a resurgence?

Can diphtheria be treated?

Who is most at risk?

What are the risks of an outbreak here?

How often are booster doses required?

What can pharmacists do?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions